Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real World Study of Pyrotinib in First-Line HER2 Positive Advanced Breast Cancer
NCT06495541Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 24.3 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06495541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495541.